Dx&Vx Signs Strategic Partnership with ProBio for Novel Drug Development
- Strategic partnership established for the development of proprietary anti-cancer antibodies
- Progress in lead identification for global clinical goals
On September 13th, Dx&Vx announced that it had entered into a strategic partnership with ProBio, a global CDMO company. Dx&Vx has embarked on a journey towards global clinical development.
Felix Zhu, Assistant Vice President in Antibody PD&MSAT department of ProBio (left) Han Sung-jun, CTO of Dx&Vx (right)
Teams of ProBio and Dx&Vx posing for a group photo after the signing ceremony
The partnership signing ceremony, held at Dx&Vx's Gasan-dong headquarters, was attended by Dx&Vx's CTO, Han Sung-jun, Avixgen's Vice President Byoungjin Kim(a subsidiary of Dx&Vx), and Felix Zhu, Assistant Vice President of ProBio's Antibody PD&MSAT department. Dx&Vx expects to secure an additional pipeline through this strategic partnership.
ProBio is a global subsidiary of GenScript. The company offers end-to-end CDMO services from drug discovery to commercialization in CGT, vaccine, antibody and recombinant protein drug with proactive strategies, professional solutions and efficient processes, it is anticipated that there will be significant synergies in the future. As of September 2023, ProBio has helped global clients in obtaining 30 IND approvals in the field of antibody and proteins drugs, with the fastest project receiving Emergency Use Authorization (EUA). Furthermore, ProBio serves as the antibody raw material supplier for two medical device products.
Through this strategic partnership, Dx&Vx is accelerating its development of proprietary anti-cancer antibodies. ProBio's advanced antibody discovery service will be utilized to the early development of anti-cancer antibody drugs, including lead identification, cell line development, manufacturing quality control (CMC), and preclinical sample production.
The development of anti-cancer antibody drugs in collaboration with ProBio will utilize the research capabilities of Dx&Vx, its subsidiary Avixgen, and the global network of the Coree Group.
Han Sung-jun, CTO of Dx&Vx, expressed his expectations, said, "We expect to accelerate our in-house new drug development projects and increase the chances of success through collaboration with ProBio, which has been involved in drug development for numerous global pharmaceutical companies." He also stated, "We will expand cooperation with global pharmaceutical and biotech companies with the aim of future global clinical trials. ”
Dr. Patrick Liu, Chairman and Acting CEO of ProBio, "We are pleased to partner with Dx&Vx and are honored to support this novel anti-cancer antibody project, I believe the cooperation will further show the technology and platform advantages of both parties. We will look forward to using ProBio’s rich CMC development experience to get the project to IND and commercialization to benefit patients soon."
Dx&Vx has recently been discussing collaboration with several leading companies at home and abroad to enhance its pipeline, including anti-cancer vaccines from Oxford Vacmedix and ophthalmic disease pipelines from Avixgen.
About Dx&Vx
Dx&Vx initially started with a focus on precision medical-based genomics diagnostics and research and development in the field of in vitro diagnostics. Currently, they are expanding into a total biotech healthcare business, with a primary focus on solutions involving the microbiome, AI-based companion diagnostics, and the development of new pharmaceuticals and treatments.
Presently, Dx&Vx is actively engaged in proprietary drug development and conducting licensing in/out reviews for potential therapeutic candidates. They are also achieving tangible results through various collaboration strategies, including the distribution of products and diagnostic kits utilizing the microbiome, open innovation in pharmaceutical development, and joint investments in their pipeline.
ProBio – a global CDMO
ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine, antibody and recombinant protein drug, aiming to accelerate drug development for customers. ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 60 IND approvals since October 2017.
